Dr. May replaced an independent board member who recently left the board. He is the president and CEO of Canada’s Centre for Commercialization of Regenerative Medicine and is heavily involved in the biologics space. He helped the Centre raise more than $100 million, which supported spinoff companies and helped develop academic partnerships.
AgeX Therapeutics board chairman Greg Bailey, MD, lauded the hiring, referring to Dr. May as a “globally-recognized leader in regenerative medicine.”
More articles on biologics:
Dr. Robert Brady: Robotics in spinal fusion and how the trend will develop in spine
Orthofix names DePuy, Medtronic, Biomet veteran the next CEO
Medicrea receives FDA approval for new screw device
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
